IMM Stock Overview
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Immutep Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.38 |
52 Week High | AU$0.42 |
52 Week Low | AU$0.23 |
Beta | 1.83 |
1 Month Change | 0% |
3 Month Change | 12.59% |
1 Year Change | 46.15% |
3 Year Change | -12.64% |
5 Year Change | 40.74% |
Change since IPO | 5.56% |
Recent News & Updates
Recent updates
Shareholder Returns
IMM | AU Biotechs | AU Market | |
---|---|---|---|
7D | 10.1% | 1.9% | 0.9% |
1Y | 46.2% | -7.7% | 5.6% |
Return vs Industry: IMM exceeded the Australian Biotechs industry which returned -7.7% over the past year.
Return vs Market: IMM exceeded the Australian Market which returned 5.6% over the past year.
Price Volatility
IMM volatility | |
---|---|
IMM Average Weekly Movement | 6.7% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.6% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IMM has not had significant price volatility in the past 3 months.
Volatility Over Time: IMM's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
IMM fundamental statistics | |
---|---|
Market cap | AU$457.70m |
Earnings (TTM) | -AU$40.50m |
Revenue (TTM) | AU$3.93m |
136.1x
P/S Ratio-13.2x
P/E RatioIs IMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMM income statement (TTM) | |
---|---|
Revenue | AU$3.93m |
Cost of Revenue | AU$37.72m |
Gross Profit | -AU$33.79m |
Other Expenses | AU$6.71m |
Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.034 |
Gross Margin | -859.57% |
Net Profit Margin | -1,030.32% |
Debt/Equity Ratio | 0.8% |
How did IMM perform over the long term?
See historical performance and comparison